# A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.

> **NCT02579226** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 72 (actual)

## Conditions studied

- Advanced Solid Tumours

## Interventions

- **DRUG:** AZD2811

## Key facts

- **NCT ID:** NCT02579226
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-28
- **Primary completion:** 2020-02-07
- **Final completion:** 2020-04-03
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2020-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02579226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02579226, "A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02579226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*